Compare BlackRock Technology and Private Equity Term Trust (BTX) vs Agios Pharmaceuticals, Inc. (AGIO) vs Vertex Pharmaceuticals Incorporated (VRTX) Stock

Vertex Pharmaceuticals Incorporated (VRTX) offers the better valuation at 31.2x trailing P/E (24.7x forward), making it the more compelling value choice. Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Vertex Pharmaceuticals Incorporated (VRTX) is the cheapest at 31.2x versus BlackRock Technology and Private Equity Term Trust at 38.9x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to -45.5% for BlackRock Technology and Private Equity Term Trust (BTX). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus BTX's -45.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus BlackRock Technology and Private Equity Term Trust's 1.16β — meaning BTX is approximately 164% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 20% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

BlackRock Technology and Private Equity Term Trust (BTX) is the more profitable company, earning 87.7% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 87.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTX leads at 87.7% versus -873.9% for AGIO. At the gross margin level — before operating expenses — BTX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AGIO: 47.2% to $41.50.

In this comparison, BTX (12.9% yield) pays a dividend. AGIO, VRTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +425.4% 10Y return). Both have compounded well over 10 years (VRTX: +425.4%, AGIO: -40.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: BTX is a small-cap income-oriented stock; AGIO is a small-cap quality compounder stock; VRTX is a mid-cap quality compounder stock. BTX pays a dividend while AGIO, VRTX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.